Home/Filings/4/0000950170-23-070882
4//SEC Filing

SIMPSON TODD E 4

Accession 0000950170-23-070882

CIK 0001060736other

Filed

Dec 14, 7:00 PM ET

Accepted

Dec 15, 6:42 PM ET

Size

62.1 KB

Accession

0000950170-23-070882

Insider Transaction Report

Form 4
Period: 2023-12-14
SIMPSON TODD E
Chief Financial Officer
Transactions
  • Disposition to Issuer

    Performance Stock Units

    2023-12-1411,4000 total
    Common stock (11,400 underlying)
  • Disposition to Issuer

    Common Stock

    2023-12-14$229.00/sh93,292$21,363,8680 total
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-141,3010 total
    Exercise: $76.86Exp: 2028-08-30Common stock (1,301 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1447,9040 total
    Exercise: $76.86Exp: 2028-08-30Common stock (47,904 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1449,2320 total
    Exercise: $72.64Exp: 2029-08-30Common stock (49,232 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1420,7740 total
    Exercise: $161.82Exp: 2030-08-17Common stock (20,774 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-141,3100 total
    Common stock (1,310 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-1411,5850 total
    Common stock (11,585 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-146,6660 total
    Common stock (6,666 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-141,3950 total
    Common stock (1,395 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-145,5470 total
    Common stock (5,547 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-1414,7460 total
    Common stock (14,746 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-144,1200 total
    Common stock (4,120 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-1414,2510 total
    Common stock (14,251 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-149830 total
    Common stock (983 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-141,3330 total
    Exercise: $72.64Exp: 2029-08-30Common stock (1,333 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-146360 total
    Exercise: $161.82Exp: 2030-08-17Common stock (636 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-146420 total
    Exercise: $155.87Exp: 2031-08-16Common stock (642 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1426,4270 total
    Exercise: $155.87Exp: 2031-08-16Common stock (26,427 underlying)
  • Disposition to Issuer

    Stock Options (Right to Buy)

    2023-12-1410,5260 total
    Exercise: $34.20Exp: 2026-05-09Common stock (10,526 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-143,2760 total
    Common stock (3,276 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-146560 total
    Common stock (656 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-141,6390 total
    Common stock (1,639 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-141,8270 total
    Common stock (1,827 underlying)
  • Disposition to Issuer

    Restricted Stock Units

    2023-12-142,1580 total
    Common stock (2,158 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-143,2760 total
    Common stock (3,276 underlying)
  • Disposition to Issuer

    Performance Stock Units

    2023-12-141,9660 total
    Common stock (1,966 underlying)
Footnotes (8)
  • [F1]Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
  • [F2]Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
  • [F3]Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
  • [F4]Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.
  • [F5]Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
  • [F6]Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance.
  • [F7]Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU.
  • [F8]Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.

Documents

1 file

Issuer

Seagen Inc.

CIK 0001060736

Entity typeother

Related Parties

1
  • filerCIK 0001216477

Filing Metadata

Form type
4
Filed
Dec 14, 7:00 PM ET
Accepted
Dec 15, 6:42 PM ET
Size
62.1 KB